Genevation LTD develops personalized mRNA vaccines using in vitro transcription technology, targeting unique neo-antigens identified from patient biopsies to create tailored cancer therapies. This approach addresses the need for effective, non-toxic treatments that specifically combat individual cancer profiles, enhancing patient survival and quality of life.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often lack the precision needed to target individual cancer profiles, leading to toxic side effects and limited effectiveness. The development of tailored therapies is hindered by the complexity of identifying unique neo-antigens present on cancer cells.
Solution
Genevation LTD is developing personalized mRNA vaccines that target neo-antigens specific to each patient's tumor. The company utilizes in vitro transcription (IVT) technology and advanced genomics to create individualized cancer therapies. By analyzing patient biopsies, Genevation identifies mutations and neo-antigens unique to the patient's cancer cells. This information is then used to design and manufacture mRNA vaccines tailored to stimulate the patient's immune system to specifically target and destroy cancer cells, offering a potentially more effective and less toxic treatment option. The company is currently engaged in pre-clinical trials.
Target Audience
The primary target audience includes cancer patients seeking personalized treatment options and oncologists looking for more effective and less toxic therapies.
Features
- Identification of patient-specific neo-antigens through advanced sequencing of tumor biopsies
- Design and production of personalized mRNA vaccines using in vitro transcription (IVT) technology
- Targeted cancer therapy that stimulates the patient's immune system to recognize and eliminate cancer cells
- Rapid vaccine development timeline, producing personalized vaccines in approximately two weeks
- Integration of genomics, IVT technology, and immuno-oncology for personalized cancer treatments